While initial trials of investigational compounds have shown promise in halting the highly fatal virus, public health officials stressed Thursday that remaining alive is merely an observational outcome.
GENEVA — As the current Ebola outbreak widens, an international coalition of scientists has moved rapidly to test several experimental treatments, while simultaneously urging the global community not to jump to conclusions just because symptomatic patients have stopped hemorrhaging from their mucous membranes.
Preliminary data from early-stage trials involving investigational monoclonal antibodies, such as those developed by Mapp Biopharmaceutical, suggest an initial positive trend in viral clearance. The findings, which have yet to be peer-reviewed, track a cohort of 42 individuals infected with the Zaire ebolavirus. While 39 of those patients exhibited a self-reported reduction in catastrophic organ failure within 48 hours of administration, authors of the pre-print study were quick to note the small sample size, emphasizing that a sudden return to baseline health cannot definitively be linked to the intervention.
To establish a true causal mechanism, researchers noted, half the patients would need to be given a placebo saline drip and closely monitored for liquefaction to rule out the possibility that the trial group simply decided to get better on their own.
While survival is certainly an encouraging secondary endpoint, we must be careful not to conflate not dying an agonizing, highly contagious death with therapeutic efficacy.
Dr. Vlahos added that several confounding variables could explain why the treated cohort was suddenly able to sit up, ask for water, and walk out of the quarantine ward. He cited potential factors including seasonal variations in viral loads, improved hospital hydration protocols, or mere statistical noise inherent in longitudinal observational cohorts. The 95 percent confidence interval regarding the patients' continued existence remains uncomfortably broad, he warned.
Furthermore, Dr. Vlahos disclosed that his laboratory receives funding from a competing pharmaceutical firm developing a separate antiviral compound, though he noted in an appendix that this financial conflict of interest was adjusted for in a multivariate analysis and found to be benign.
At press time, the World Health Organization issued a bulletin reminding field doctors that administering the promising compounds remains strictly off-label. The agency recommended maintaining a cautious, wait-and-see approach to the widening outbreak in order to guarantee robust, unimpeachable p-values before any emergency interventions are formalized.